An 89-year-old male case was hospitalized in the COVID-19 department. His computerized chest tomography scan showed nodular opacities with glass halo including peripheral distribution. The patient showed active brucellosis.Finally, his respiratory symptoms and the radiologic images had got better and the second SARS-COV-2 test and the serologic tests were negative

ECMO is a selectively available therapeutic option, generally at a large-size referral healthcare system. In a single-center experience of use of veno-venous ECMO for COVID-19 ARDS in a medium-size healthcare system during the pandemic, West and colleagues in their study have convincingly demonstrated that ECMO can become a broadly available therapeutic option without compromising quality.

Title: Posterior Reversible Encephalopathy Syndrome and Necrotizing Enterocolitis in a Pediatric Patient with Medulloblastoma Infected with COVID-19

We reported an association between SARS-CoV-2 infection and Guillain-Barre´ syndrome (GBS). From 37 patients with GBS, Previous SARS-CoV-2 infection clues, including fever, cough, and diarrhea were recorded in 18 patients. Among them, SARS-CoV-2 IgG was detected in 7 patients, considered confirmed cases. SARS-CoV-2 PCR was positive in just 1 patient.

Fluvoxamine is a selective-serotonin reuptake inhibitor (SSRI), well-tolerated and widely available, usually used in the management of mental-health conditions. Fluvoxamine is also a sigma-1 agonist with high affinity to this receptor and this pharmacodynamical effect has been being portrayed as the main explanation in emerging evidence about the potential of using fluvoxamine in COVID-19 patients. This systematic review was conducted according to the PRISMA guidelines. The search was run in MEDLINE, Web of Science, and CENTRAL from the Cochrane databases. The study protocol was registered in PROSPERO (CRD42022302025). Our aim was to assess the present evidence for therapeutic role of fluvoxamine in COVID-19 patients, the review included studies which evaluate the effect of fluvoxamine in COVID-19 patients. The main outcomes evaluated in the review were: mortality, need for hospitalization (outpatients) and clinical deterioration. The quality control of the selected articles was made using Cochrane’s Risk of Bias tool for the randomized controlled trials (RCTs) and the ROBINS-I criteria for non-randomized studies. A total of 4 studies were included in the final qualitative analysis of the review, 2 of which were RCTs, and the others were open-label prospective cohorts. 3 studies assessed outpatient population and 1 evaluated ICU population. Overall, the 4 studies included a total of 1864 participants. In conclusion, 3 studies with outpatients showed that fluvoxamine treatment can prevent clinical deterioration, hospitalisation, or proxy-hospitalisation. The only study with patients hospitalized in the ICU also demonstrated a therapeutic benefit reducing overall mortality.

It is important to increase the awareness of head and neck surgeons about the recent surge of craniofacial mucormycosis in COVID-19 patients, because early diagnosis and treatment are essential to improve the outcomes. Here, we describe clinical features, treatment protocols, and outcomes of treatment in 8 patients with COVID-19-associated mucormycosis

Myositis is one of the uncommon adverse events following COVID--19 vaccination, and its mechanism is still unclear. In the hope of aiding in its better understanding, we present a case of myositis following the first dose of the ChAdOx1 nCoV-19 Corona Virus Vaccine, evidenced by serology and MRI.

COVID-19 showed different characteristics and many cases showed clinical manifestations that could not be attributed to other conditions. We present a 22-year-old female had an uneventful recovery from COVID-19 and after that, she developed a cytokine storm and a worsening clinical condition two days after dental root canal therapy.

Length of anticoagulation for thrombotic events related to COVID-19 is unknown. We present a patient with COVID-19 complicated by a thrombotic anterior STEMI and multiple left ventricular (LV) thrombi that resolved after 8 weeks of anticoagulation. We suggest a shorter length of anticoagulation with COVID-19 related LV thrombus.

Re letter to British Journal of Clinical Pharmacology

Joint involvement in COVID-19 may occur at different stages of the disease and maybe represented by acute arthritis.We report Two cases of COVID-19.Both of our cases are consistent with what has been reported in the literature strengthen the necessity of wider studies to identify rheumatologic manifestations after surviving COVID-19.

COVID-19, TB and HIV are infectious diseases of global public health concern. Triple Co-infection with these diseases can create a diagnostic and therapeutic dilemma. We present a case of a young Cameroonian woman with SARS-CoV-2 -- HIV-TB triple co-infection. Early diagnosis and appropriate management yielded an excellent outcome.

Asthma 17q21 Polymorphism Associates with COVID-19 in Children

A potential immunological silver bullet for COVID-19: the trivalent chimpanzee adenoviral serotype-68 vector (Tri:ChAd)

COVID-19 is a multi-system disorder. Bell's palsy is a lower motor neuron lesion that is uncommon after COVID-19 or related vaccinations. We documented two incidences of Bell's palsy in this study, one after she was exposed to COVID-19 and the other after he was exposed to AstraZeneca Vaccine.

Background: Although avian coronavirus infectious bronchitis virus (IBV) and SARS-CoV-2 belong to different genera of the Coronaviridae family, exposure to IBV may result in the development of cross-reactive antibodies to SARS-CoV-2 due to homologous epitopes. We aimed to investigate whether antibody responses to IBV cross-react with SARS-CoV-2 in poultry farm personnel who are occupationally exposed to aerosolized IBV vaccines. Methods: We analyzed sera from poultry farm personnel, COVID-19 patients, and pre-pandemic controls. IgG levels against the SARS-CoV-2 antigens S1, RBD, S2, and N and peptides corresponding to the SARS-CoV-2 ORF3a, N, and S proteins as well as whole virus antigens of the four major S1-genotypes 4/91, IS/1494/06, M41, and D274 of IBV were investigated by in-house ELISAs. Moreover, live-virus neutralization test (VNT) was performed. Results: A subgroup of poultry farm personnel showed elevated levels of specific IgG for all tested SARS-CoV-2 antigens compared to pre-pandemic controls. Moreover, poultry farm personnel, COVID-19 patients, and pre-pandemic controls showed specific IgG antibodies against IBV strains. These antibody titers were higher in long-term vaccine implementers. We observed a strong correlation between IBV-specific IgG and SARS-CoV-2 S1-, RBD-, S2-, and N-specific IgG in poultry farm personnel compared to pre-pandemic controls and COVID-19 patients. However, no neutralization was observed for these cross-reactive antibodies from poultry farm personnel using the VNT. Conclusion: We report here for the first time the detection of cross-reactive IgG antibodies against SARS-CoV-2 antigens in humans exposed to IBV vaccines. These findings have implications for future vaccination strategies and possibly cross-reactive T cell immunity.

A document by Sebastian Velasteguí. Click on the document to view its contents.

Although the presence of morphea following COVID-19 has been rarely reported, development of its generalized form following COVID-19 vaccination has not been reported yet. Here, we reported the first case of generalized morphea following COVID-19 vaccination and another similar case following SARS-Cov-2 infection. Other etiologic factors were also dealt with

COVID-19 related MIS-C (Multisystem inflammatory syndrome in children) can present with cardiovascular complications like shock, arrhythmias, pericardial effusion, and coronary artery dilatation. The majority of MIS-C associated coronary artery abnormalities are dilation or small aneurysms which are transient and resolve in a few weeks[[1, 2]](#ref-0001). We present here a case of a 3-month-old child who was noted to have giant aneurysms of her coronary arteries (LAD and RCA) twenty-six days after testing positive for COVID-19. She was treated with IVIG, infliximab, and glucocorticoids along with aspirin, clopidogrel and enoxaparin. She did not show any signs of coronary ischemia or cardiac dysfunction but continued to have persistent giant coronary artery aneurysms involving the LAD (z-score ~35) and RCA (z-score ~30) [Fig. 1]. This study emphasizes the importance of early detection and aggressive management of MIS-C to prevent potentially life-threatening consequences.

A Pneumothorax in the Setting of COVID-19 Associated Pneumatoceles in a Pediatric PatientEsther Blondeau-Lecomte, BA1, Nancy Joseph, MBBS11Department of Pediatrics, University of Florida, Gainesville, FL, USA

Aim: We aimed to examine fetal cardiac output (CO) in patients who recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Materials: This prospective study included 48 pregnant women recovered from SARS-CoV-2 infection and 50 control cases. SARS-CoV-2 infection was diagnosed by polymerase chain reaction (PCR) test in patients. Fetal echocardiographic evaluations were performed at 24-37 weeks of gestation in pregnant women who recovered from the infection and control group. Results: The median value of ultrasound evaluation was 34 (2.6) weeks of gestation in the recovery from the SARS-CoV-2 infection (RSI) group, and 32 (7.6) weeks in the control group (p=0.565). Left cardiac output (LCO) z score was significantly lower in the RSI group than the control group (p=0,041). LCO and combine cardiac output (CCO) z score were significantly lower in the severe disease group than mild, moderate disease groups, and controls (p=0,019 and p=0,013). CCO (mL/min/kg) was decreased in the severe disease group when compared with control and mild disease groups (p=0,044). Fetal distress, preterm delivery rate, and neonatal intensive care unit (NICU) admission were found to be higher in the severe disease group compared to the control group (p=0,010, p=0,009, and p<0,001 respectively). Conclusion: In the present study, fetal cardiac output in pregnant women with recovery from SARS-CoV-2 infection was found significantly decreased, especially in whom had severe diseases. Placental dysfunction and inflammatory cytokines might cause fetal cardiac changes. Further studies could be clarified on the impact of SARS-CoV-2 infection on fetal cardiac function.

A document by Sergio Bonini. Click on the document to view its contents.

Autopsy was performed on a COVID-19 patient, who suddenly died despite the extensive anti-viral and anti-inflammatory therapies. Although moderate subpleural fibrosis was seen, pathology of DAD, a well-known cause for pulmonary failure, was minimum. Instead, severe hemorrhage was observed. Therapeutic effects were indicated, however why severe hemorrhage occurred was unclear.

We report a rare case of a 50-year-old female with covid19 presented to the emergency department where supplementary oxygen is delivered via non-invasive face mask ventilation. x-ray imaging performed the existence of pneumoperitoneum. CT scan was not applicable due to the advanced status of the paient.